WEST

Freeform Search

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: ((tumor necrosis factor near2 converting enzyme) or tace) and hydroxamate

Display: 50 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ Hit List ◉ Hit Count ○ Image

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences

Search History

Today's Date: 6/19/2001

DB Name	Query	Hit Count	Set Name
JPAB,EPAB,DWPI	(adam-17) and hydroxamate	0	L9
JPAB,EPAB,DWPI	((tumor necrosis factor near2 converting enzyme) or tace) and hydroxamate	3	L8
USPT,PGPB	l6 and hydroxamate	2	L7
USPT,PGPB	tumor necrosis factor near2 converting enzyme	12	L6
USPT,PGPB	adam-17 and hydroxamate	0	L5
USPT,PGPB	l3 and @ad<19980812	2	L4
USPT,PGPB	l1 same hydroxamate	5	L3
USPT,PGPB	l1 and hydroxamate	17	L2
USPT,PGPB	tace	61	L1

```
* * * * * * * * * * * * * *
STN  Columbus  * * * * * * * *
* * * * * * * *

FILE 'HOME' ENTERED AT
15:34:13 ON 19 JUN 2001

=> file reg
COST IN U.S. DOLLARS
SINCE FILE      TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
0.15       0.15

FILE 'REGISTRY' ENTERED AT
15:34:47 ON 19 JUN 2001
USE IS SUBJECT TO THE TERMS
OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS"
FOR DETAILS.
COPYRIGHT (C) 2001 American
Chemical Society (ACS)

STRUCTURE FILE UPDATES:   18
JUN 2001  HIGHEST RN 342370-
76-7
DICTIONARY FILE UPDATES:  18
JUN 2001  HIGHEST RN 342370-
76-7

TSCA INFORMATION NOW CURRENT
THROUGH January 11, 2001

  Please note that search-
term pricing does apply when
  conducting SmartSELECT
searches.

Structure search limits have
been increased.  See HELP
SLIMIT
for details.

=> e tace/cn
E1            1
TACCAOSIDE PERMETHYLATE/CN
E2            1     TACCH/CN
E3            2 --> TACE/CN
E4            1     TACE
(PHARMACEUTICAL)/CN
E5            1     TACE
PROTEINASE/CN
E6            1     TACEF/CN
E7            1     TACFOAM
VCPAC/CN
E8            1
TACHARANITE/CN
E9            1
TACHARANITE
(AL2CA12H6(SIO3)18.15H2O)/CN
E10           1
TACHIGAREN/CN
E11           1
TACHIOGROSIDE B/CN
E12           1
TACHIOSIDE/CN

=> s e3
L1            2 TACE/CN

=> d

L1   ANSWER 1 OF 2  REGISTRY
COPYRIGHT 2001 ACS
RN   151769-16-3  REGISTRY
CN   Proteinase, pro-tumor
necrosis factor (9CI)  (CA
INDEX NAME)
OTHER NAMES:
CN   ADAM17 proteinase
CN   Metalloproteinase
ADAM17
CN   Pro tumor necrosis
factor cleavage enzyme
CN   Pro-tumor necrosis
factor-.alpha.-processing
enzyme
CN     ***TACE***
CN   TACE proteinase
CN   TNF-.alpha. convertase
CN   TNF-.alpha. converting
enzyme
CN   TNF-.alpha. processing
protease
CN   Tumor necrosis factor
.alpha. convertase
CN   Tumor necrosis factor-
.alpha. converting enzyme
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   BIOSIS,
BIOTECHNO, CA, CAPLUS, CIN,
EMBASE, TOXLIT, USPATFULL

*** STRUCTURE DIAGRAM IS NOT
AVAILABLE ***
              136 REFERENCES
IN FILE CA (1967 TO DATE)
                3 REFERENCES
TO NON-SPECIFIC DERIVATIVES
IN FILE CA
              137 REFERENCES
IN FILE CAPLUS (1967 TO
DATE)


=> d 2

L1   ANSWER 2 OF 2  REGISTRY
COPYRIGHT 2001 ACS
RN   569-57-3  REGISTRY
CN   Benzene, 1,1',1''-(1-
chloro-1-ethenyl-2-
ylidene)tris[4-methoxy-
(9CI)  (CA
     INDEX NAME)
OTHER CA INDEX NAMES:
CN   Chlorotrianisene (6CI)
CN   Ethylene, chlorotris(p-
methoxyphenyl)- (7CI, 8CI)
OTHER NAMES:
CN   Anisene
CN   Chlorotris(p-
methoxyphenyl)ethylene
CN   Chlortrianizen
CN   Clorestrolo
CN   Clorotrisin
CN   Hormonisene
CN   Khlortrianizen
CN   Merbentul
CN   Metace
CN   NSC 10108
CN   Rianil
CN     ***Tace***
CN   Tace (pharmaceutical)
CN   Tri-p-
anisylchloroethylene
CN   Trianisylchloroethylene
CN   Tris(p-
methoxyphenyl)chloroethylene
FS   3D CONCORD
DR   13003-83-3
MF   C23 H21 Cl O3
LC   STN Files:   ANABSTR,
BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA,
       CANCERLIT, CAOLD,
CAPLUS, CBNB, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CIN,
       CSCHEM, DDFU,
DIOGENES, DRUGU, EMBASE,
HODOC*, HSDB*, IPA, MEDLINE,
       MRCK*, NIOSHTIC,
PROMT, RTECS*, SPECINFO,
TOXLINE, TOXLIT, USAN,
       USPATFULL
         (*File contains
numerically searchable
property data)
     Other Sources:
EINECS**, WHO
         (**Enter CHEMLIST
File for up-to-date
regulatory information)


/ Structure 1 in file .gra /

              98 REFERENCES
IN FILE CA (1967 TO DATE)
               4 REFERENCES
TO NON-SPECIFIC DERIVATIVES
IN FILE CA
              98 REFERENCES
IN FILE CAPLUS (1967 TO
DATE)
              30 REFERENCES
IN FILE CAOLD (PRIOR TO
1967)


=> set sel cont
SET COMMAND COMPLETED

=> sel l1 1 name
E1 THROUGH E11 ASSIGNED

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT
AUTHORIZED
COST IN U.S. DOLLARS
SINCE FILE      TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
7.99       8.14

INDEX 'ADISALERTS,
ADISINSIGHT, AGRICOLA,
```

```
ANABSTR, AQUASCI,
BIOBUSINESS,
       BIOCOMMERCE, BIOSIS,
BIOTECHABS, BIOTECHDS,
BIOTECHNO, CABA, CANCERLIT,
       CAPLUS, CEABA-VTB,
CEN, CIN, CONFSCI, CROPB,
CROPU, DDFB, DDFU, DGENE,
       DRUGB, DRUGLAUNCH,
DRUGMONOG2, DRUGNL, ...'
ENTERED AT 15:36:30 ON 19
JUN 2001

59 FILES IN THE FILE LIST IN
STNINDEX

Enter SET DETAIL ON to see
search term postings or to
view
search error messages that
display as 0* with SET
DETAIL OFF.

=> s el-11
          6   FILE
ADISALERTS
         10   FILE
ADISINSIGHT
   2 FILES SEARCHED...
          1   FILE AGRICOLA
   4 FILES SEARCHED...
          1   FILE AQUASCI
          9   FILE
BIOBUSINESS
          2   FILE
BIOCOMMERCE
        289   FILE BIOSIS
   8 FILES SEARCHED...
          8   FILE
BIOTECHABS
          8   FILE BIOTECHDS
         92   FILE BIOTECHNO
  11 FILES SEARCHED...
          7   FILE CABA
        256   FILE CANCERLIT
  13 FILES SEARCHED...
        274   FILE CAPLUS
  14 FILES SEARCHED...
          8   FILE CIN
         12   FILE CONFSCI
  18 FILES SEARCHED...
          1   FILE CROPU
  20 FILES SEARCHED...
         45   FILE DDFB
         63   FILE DDFU
  22 FILES SEARCHED...
         94   FILE DGENE
         45   FILE DRUGB
  24 FILES SEARCHED...
         12   FILE
DRUGMONOG2
          3   FILE DRUGNL
         70   FILE DRUGU
  28 FILES SEARCHED...
          2   FILE
DRUGUPDATES
          6   FILE EMBAL
  30 FILES SEARCHED...
        334   FILE EMBASE
  31 FILES SEARCHED...
        124   FILE ESBIOBASE
  32 FILES SEARCHED...
          1   FILE FSTA
        100   FILE GENBANK
  37 FILES SEARCHED...
         33   FILE IFIPAT
         56   FILE JICST-
EPLUS
  40 FILES SEARCHED...
         39   FILE LIFESCI
  43 FILES SEARCHED...
        289   FILE MEDLINE
          2   FILE NIOSHTIC
  45 FILES SEARCHED...
          2   FILE NTIS
  47 FILES SEARCHED...
        104   FILE PASCAL
  48 FILES SEARCHED...
         11   FILE PHAR
         16   FILE PHIN
         96   FILE PROMT
  52 FILES SEARCHED...
        290   FILE SCISEARCH
         54   FILE TOXLINE
  55 FILES SEARCHED...
         52   FILE TOXLIT
         87   FILE USPATFULL
  57 FILES SEARCHED...
         57   FILE WPIDS
         57   FILE WPINDEX

  45 FILES HAVE ONE OR MORE
ANSWERS,   59 FILES SEARCHED
IN STNINDEX

L2   QUE ("ADAM17
PROTEINASE"/BI OR
"METALLOPROTEINASE
ADAM17"/BI OR "PRO TUMOR
          NECROSIS FACTOR
CLEAVAGE ENZYME"/BI OR "PRO-
TUMOR NECROSIS FACTOR-.AL
          PHA.-PROCESSING
ENZYME"/BI OR "TACE
PROTEINASE"/BI OR TACE/BI OR
"TNF-
          .ALPHA.
CONVERTASE"/BI OR "TNF-
.ALPHA. CONVERTING
ENZYME"/BI OR "TNF-.
          ALPHA. PROCESSING
PROTEASE"/BI OR "TUMOR
NECROSIS FACTOR .ALPHA.
CONVE
          RTASE"/BI OR "TUMOR
NECROSIS FACTOR-.ALPHA.
CONVERTING ENZYME"/BI)

=> s l2 and hydroxamate
   3 FILES SEARCHED...
          12   FILE BIOSIS
   8 FILES SEARCHED...
           9   FILE BIOTECHNO
  11 FILES SEARCHED...
           7   FILE CANCERLIT
  13 FILES SEARCHED...
          24   FILE CAPLUS
  14 FILES SEARCHED...
  18 FILES SEARCHED...
  20 FILES SEARCHED...
           2   FILE DDFU
  22 FILES SEARCHED...
  24 FILES SEARCHED...
           2   FILE DRUGU
  28 FILES SEARCHED...
  30 FILES SEARCHED...
          15   FILE EMBASE
  31 FILES SEARCHED...
          11   FILE ESBIOBASE
  32 FILES SEARCHED...
           2   FILE IFIPAT
  39 FILES SEARCHED...
           3   FILE LIFESCI
  42 FILES SEARCHED...
          11   FILE MEDLINE
  44 FILES SEARCHED...
  46 FILES SEARCHED...
  48 FILES SEARCHED...
           1   FILE PROMT
  52 FILES SEARCHED...
          13   FILE SCISEARCH
           3   FILE TOXLINE
  55 FILES SEARCHED...
           1   FILE TOXLIT
          23   FILE USPATFULL
  57 FILES SEARCHED...
           6   FILE WPIDS
           6   FILE WPINDEX

  18 FILES HAVE ONE OR MORE
ANSWERS,   59 FILES SEARCHED
IN STNINDEX

L3   QUE L2 AND HYDROXAMATE

=> s l3 and py<1999
          0*   FILE
ADISINSIGHT
   3 FILES SEARCHED...
   5 FILES SEARCHED...
   7 FILES SEARCHED...
           6   FILE BIOSIS
   8 FILES SEARCHED...
           5   FILE BIOTECHNO
  11 FILES SEARCHED...
           4   FILE CANCERLIT
  13 FILES SEARCHED...
          12   FILE CAPLUS
  14 FILES SEARCHED...
  17 FILES SEARCHED...
          0*   FILE CONFSCI
  19 FILES SEARCHED...
  21 FILES SEARCHED...
           2   FILE DDFU
  23 FILES SEARCHED...
  26 FILES SEARCHED...
           2   FILE DRUGU
  29 FILES SEARCHED...
           5   FILE EMBASE
  31 FILES SEARCHED...
           5   FILE ESBIOBASE
  32 FILES SEARCHED...
          0*   FILE FOREGE
  37 FILES SEARCHED...
           2   FILE IFIPAT
  40 FILES SEARCHED...
           1   FILE LIFESCI
  42 FILES SEARCHED...
          0*   FILE MEDICONF
           5   FILE MEDLINE
  44 FILES SEARCHED...
  46 FILES SEARCHED...
  48 FILES SEARCHED...
```

```
        0*   FILE PHAR
  52 FILES SEARCHED...
        5    FILE SCISEARCH
  54 FILES SEARCHED...
        1    FILE TOXLINE
  55 FILES SEARCHED...
        6    FILE USPATFULL
  57 FILES SEARCHED...
        1    FILE WPIDS
  58 FILES SEARCHED...
        1    FILE WPINDEX

  16 FILES HAVE ONE OR MORE
ANSWERS,    59 FILES SEARCHED
IN STNINDEX

L4    QUE L3 AND PY<1999

=> d rank
F1            12    CAPLUS
F2             6    BIOSIS
F3             6    USPATFULL
F4             5    BIOTECHNO
F5             5    EMBASE
F6             5    ESBIOBASE
F7             5    MEDLINE
F8             5    SCISEARCH
F9             4    CANCERLIT
F10            2    DDFU
F11            2    DRUGU
F12            2    IFIPAT
F13            1    LIFESCI
F14            1    TOXLINE
F15            1    WPIDS
F16            1    WPINDEX


=> file f1-2 f4-16
COST IN U.S. DOLLARS
SINCE FILE       TOTAL

ENTRY     SESSION
FULL ESTIMATED COST
27.90       36.04

FILE 'CAPLUS' ENTERED AT
16:13:57 ON 19 JUN 2001
USE IS SUBJECT TO THE TERMS
OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS"
FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN
CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT
16:13:57 ON 19 JUN 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'BIOTECHNO' ENTERED AT
16:13:57 ON 19 JUN 2001
COPYRIGHT (C) 2001 Elsevier
Science B.V., Amsterdam. All
rights reserved.

FILE 'EMBASE' ENTERED AT
16:13:57 ON 19 JUN 2001
COPYRIGHT (C) 2001 Elsevier
Science B.V.  All rights
reserved.

FILE 'ESBIOBASE' ENTERED AT
16:13:57 ON 19 JUN 2001
COPYRIGHT (C) 2001 Elsevier
Science B.V., Amsterdam. All
rights reserved.

FILE 'MEDLINE' ENTERED AT
16:13:57 ON 19 JUN 2001

FILE 'SCISEARCH' ENTERED AT
16:13:57 ON 19 JUN 2001
COPYRIGHT (C) 2001 Institute
for Scientific Information
(ISI) (R)

FILE 'CANCERLIT' ENTERED AT
16:13:57 ON 19 JUN 2001

FILE 'DDFU' ACCESS NOT
AUTHORIZED

FILE 'DRUGU' ENTERED AT
16:13:57 ON 19 JUN 2001
COPYRIGHT (C) 2001 DERWENT
INFORMATION LTD

FILE 'IFIPAT' ENTERED AT
16:13:57 ON 19 JUN 2001
COPYRIGHT (C) 2001 IFI
CLAIMS(R) Patent Services
(IFI)

FILE 'LIFESCI' ENTERED AT
16:13:57 ON 19 JUN 2001
COPYRIGHT (C) 2001 Cambridge
Scientific Abstracts (CSA)

FILE 'TOXLINE' ENTERED AT
16:13:57 ON 19 JUN 2001

FILE 'WPIDS' ENTERED AT
16:13:57 ON 19 JUN 2001
COPYRIGHT (C) 2001 DERWENT
INFORMATION LTD

FILE 'WPINDEX' ACCESS NOT
AUTHORIZED

=> s l4
     1 FILES SEARCHED...
     2 FILES SEARCHED...
     3 FILES SEARCHED...
     4 FILES SEARCHED...
     5 FILES SEARCHED...
     6 FILES SEARCHED...
     7 FILES SEARCHED...
     8 FILES SEARCHED...
    10 FILES SEARCHED...
    11 FILES SEARCHED...
    12 FILES SEARCHED...
L5           54 L4

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6           15 DUP REM L5
(39 DUPLICATES REMOVED)
                 ANSWERS '1-
12' FROM FILE CAPLUS
                 ANSWER '13'
FROM FILE BIOSIS
                 ANSWER '14'
FROM FILE DRUGU
                 ANSWER '15'
FROM FILE IFIPAT

=> d bib ab 1-15

L6   ANSWER 1 OF 15  CAPLUS
COPYRIGHT 2001 ACS
DUPLICATE 1
AN   1998:646966  CAPLUS
DN   130:11872
TI   Phorbol Ester-Induced
Juxtamembrane Cleavage of
Angiotensin-Converting
     Enzyme Is Not Inhibited
by a Stalk Containing
Intrachain Disulfides
AU   Schwager, Sylva L. U.;
Chubb, Anthony J.; Scholle,
Renate R.; Brandt, Wolf
     F.; Eckerskorn,
Christoph; Sturrock, Edward
D.; Ehlers, Mario R. W.
CS   Department of Medical
Biochemistry, University of
Cape Town Medical
     School, Observatory,
7925, S. Afr.
SO   Biochemistry (
***1998***  ), 37(44),
15449-15456
     CODEN: BICHAW; ISSN:
0006-2960
PB   American Chemical
Society
DT   Journal
LA   English
AB   Specialized proteases,
referred to as sheddases,
secretases, or
     membrane-protein-
solubilizing proteases
(MPSPs), solubilize the
     extracellular domains
of diverse membrane proteins
by catalyzing a
     specific cleavage in
the juxtamembrane stalk
regions of such proteins.  A
     representative MPSP (
***tumor***
***necrosis***
***factor***  -.
        ***alpha***  .
***convertase***  ) was
cloned recently and shown to
be a
     disintegrin
metalloprotease that is
inhibited by peptide
        ***hydroxamates***
including the compd. TAPI
(TNF-.alpha. protease
     inhibitor).  Substrate
determinants that specify
cleavage by MPSPs remain
     incompletely
characterized, but may
include the physicochem.
properties of
```

the stalk or unidentified recognition motifs in the stalk or the extracellular domain. We constructed a mutant angiotensin-converting enzyme (ACE) in which the stalk has been replaced with an epidermal growth factor (EGF)-like domain (ACE-JMEGF), to test the hypothesis that MPSP cleavage requires an open, comparatively unfolded or extended stalk. Wild-type ACE is a type I transmembrane (TM) ectoprotein that is efficiently solubilized by a typical MPSP activity. We found that ACE-JMEGF was solubilized inefficiently and accumulated in a cell-assocd. form on transfected Chinese hamster ovary (CHO) cells; cleavage was stimulated by phorbol ester and inhibited by TAPI, features typical of MPSP activity. Detn. of the C-terminus of sol. ACE-JMEGF revealed that, surprisingly, cleavage occurred at a Gly-Phe bond between the fifth and sixth cysteines within the third disulfide loop of the EGF-like domain. Redn. of intact CHO cells with tributylphosphine resulted in the rapid release of ACE-JMEGF (but not wild-type ACE) into the medium, suggesting that a proportion of membrane-bound ACE-JMEGF is cleaved but remains cell-assocd. via disulfide tethering. The mechanism for the release of ACE-JMEGF in the absence of chem. redn. is unclear. We conclude that the presence of a compact, disulfide-bridged domain does not per se inhibit cleavage by an MPSP activity, but ectodomain release is prevented by disulfide tethering to the TM domain.
RE.CNT 38
RE
(1) Arribas, J; J Biol Chem 1996, V271, P11376 CAPLUS
(2) Arribas, J; J Biol Chem 1997, V272, P17160 CAPLUS
(4) Beldent, V; J Biol Chem 1995, V270, P28962 CAPLUS
(5) Black, R; Nature 1997, V385, P729 CAPLUS
(7) Brakebusch, C; J Biol Chem 1994, V269, P32488 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2001 ACS
DUPLICATE 2
AN 1998:529532 CAPLUS
TI Succinate-based ***tnf*** -. ***alpha*** . ***convertase*** inhibitors: 5-azabenzimidazole as a surrogate of the amide bond at P3'.
AU Xue, Chu-Biao; He, Xiaohua; Roderick, John; DeGrado, William; Jaffee, Bruce; Covington, Maryanne; Magolda, Ron; Decicco, Carl
CS DuPont Merck Pharmaceutical Company, Wilmington, DE, 19880, USA
SO Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27 (***1998***), MEDI-046 Publisher: American Chemical Society, Washington, D. C.
CODEN: 66KYA2
DT Conference; Meeting Abstract
LA English
AB TNF-.alpha. is a key cytokine in inflammation and prodn. of TNF-.alpha. is significantly increased in inflammatory diseases such as rheumatoid arthritis. ***TNF*** -. ***alpha*** . ***convertase*** is responsible for converting the membrane-bound TNF-.alpha. precursor to the mature.sol. TNF-.alpha.. This process has been found to be inhibited by some succinate-based MMP inhibitors. As part of our efforts in the search for ***TNF*** -. ***alpha*** . ***convertase*** inhibitors, we were interested in succinate-based ***hydroxamate*** compds. with an amide bond surrogate at P3'. The discovery of 5-azabenzimidazole as a surrogate of the amide bond at P3' will be presented.

L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2001 ACS
DUPLICATE 3
AN 1998:630170 CAPLUS
DN 129:341110
TI ***TNF*** -. ***alpha*** . ***converting*** ***enzyme*** (***TACE***) is inhibited by TIMP-3
AU Amour, Augustin; Slocombe, Patrick M.; Webster, Ailsa; Butler, Michael; Knight, C. Graham; Smith, Bryan J.; Stephens, Paul E.; Shelley, Chris; Hutton, Mike; Knauper, Vera; Docherty, Andrew J. P.; Murphy, Gillian
CS Schlool of Biological Sciences, University of Cambridge, Cambridge, CB2 IQW, UK
SO FEBS Lett. (***1998***), 435(1), 39-44
CODEN: FEBLAL; ISSN: 0014-5793
PB Elsevier Science B.V.
DT Journal
LA English
AB Tumor necrosis factor-.alpha. (***TNF*** -. ***alpha*** .)-***converting*** ***enzyme*** (***TACE*** ; ADAM-17) is a membrane-bound disintegrin metalloproteinase that processes the membrane-assocd. cytokine, pro-TNF-.alpha., to a sol. form. Because of its putative involvement in inflammatory diseases, ***TACE*** represents a significant target for the design of specific synthetic inhibitors as therapeutic agents. In order to study its inhibition by TIMPs and synthetic inhibitors of metalloproteinases, the catalytic domain of mouse ***TACE*** (rTACE) was overexpressed as a sol. Ig fusion

protein from NS0O cells; rTACE was found to be well inhibited by peptide ***hydroxamate*** inhibitors as well as by TIMP-3, but not by TIMP-1, TIMP-2, or TIMP-4. These results suggest that TIMP-3, unlike the other TIMPs, may be important in the modulation of pathol. events in which TNF-.alpha. secretion is involved.

L6 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2001 ACS
DUPLICATE 4
AN 1997:70379 CAPLUS
DN 126:171901
TI Preparation of peptide derivatives as inhibitors of TNF-.alpha. secretion
IN Black, Roy A.; Fitzner, Jeffrey N.; Sleath, Paul R.
PA Immunex Corporation, USA
SO U.S., 28 pp. Cont.-in-part of U.S. Ser. No. 110, 601, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5594106	A	19970114	US 1994-292547	19940818 <--
US 5629285	A	19970513	US 1996-651363	19960522 <--

PRAI US 1993-110601 19930823
US 1994-292547 19940818
OS MARPAT 126:171901
AB Peptide derivs. having active groups capable of inhibiting ***TNF*** -. ***alpha*** . ***converting*** ***enzyme*** (***TACE***), such as ***hydroxamates*** , thiols, phosphoryls and carboxyls

X(CHR1)mCHR2CONHCHR3CO(A)nNHBNH2 [I; X = hydroxamic acid, thiol, phosphoryl, carboxyl; m = 0-2; R1, R2, R3 = independently H, alkylene(cycloalkyl), OR4, NR4R5, halo, (un)substituted C1-8 alkyl, C1-8 alkylenearyl, aryl, (un)protected natural amino acid side chain, R6R7; R4, R5 = independently H, (un)substituted C1-8 alkyl; R6 = (un)substituted C1-8 alkyl; R7 = OR4, NR4R5, halo; n = 0-2; each A = same or different (un)protected .alpha.-amino acid radical; B = (un)substituted C2-8 alkylene], pharmaceutically acceptable salts thereof, and methods for prepg. them are disclosed. I are useful in inhibiting ***TACE*** responsible for cleavage of TNF-.alpha. precursor to provide biol. active TNF-.alpha.. Thus, coupling of MeO2CCH2CH(CH2CHMe2)CO2Su (Su = succinimido; prepn. given) with dipeptide H-Nal-Ala-NHCH2CH2NHZ (Nal = 2-naphthyl-L-alanine; Z = CO2CH2Ph; prepn given), condensation with hydroxylamine and catalytic hydrogenolysis, gave ***hydroxamate*** inhibitor II. II shows selective in vitro and in vivo inhibition of TNF-.alpha. secretion.

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2001 ACS
DUPLICATE 5
AN 1997:332335 CAPLUS
DN 127:132564
TI Partial purification and characterization of a tumor necrosis factor-.alpha. converting activity
AU Robache-Gallea, Sylvie; Bruneau, Jean Michel; Robbe, Hugue; Morand, Valerie; Capdevila, Cecile; Bhatnagar, Neerja; Chouaib, Salem; Roman-Roman, Sergio
CS Domaine Therapeutique Immunologie, Roussel-Uclaf, Romainville, F-93230, Fr.
SO Eur. J. Immunol. (***1997***), 27(5), 1275-1282
CODEN: EJIMAF; ISSN: 0014-2980
PB VCH
DT Journal
LA English
AB Tumor necrosis factor (TNF)-.alpha. is initially synthesized as an extracellular membrane-assocd. 26-kDa protein that is further cleaved at Ala76-Val77 to yield the sol. 17-kDa form. Peptide- ***hydroxamate*** metalloproteinase inhibitors were reported to block the proteolytic processing of TNF-.alpha., thus suggesting that the putative ***TNF*** -. ***alpha*** . ***converting*** ***enzyme*** (***TACE***) is a Zn-dependent metalloendopeptidase. A TNF-.alpha. converting activity (TACA) was characterized that cleaves in vitro the human 26-kDa TNF-.alpha. at the physiol. processing site. The chromatog. steps followed for purifn. and the use of a panel of proteinase inhibitors indicate that the enzyme responsible for TACA is a membrane glycosylated metalloendopeptidase which is most likely different from the matrix-degrading metalloproteinases. The failure of TACA to process a Val77 .fwdarw. Gly77 precursor mutant emphasizes the importance of hydrophobic residue at P1' position. TACA is not able to cleave the mouse pro-TNF-.alpha. and does not catalyze in vitro the processing of other transmembrane proteins susceptible to metalloproteinase-mediated shedding, such as interleukin-6 or TNF receptors. It was suggested the existence of an enzyme specific for TNF-.alpha. within the metalloproteinases involved in the processing/shedding of a no. of cytokines and cytokine receptors.

L6 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2001 ACS
DUPLICATE 6
AN 1997:43929 CAPLUS

DN 126:154267
TI Purification of ADAM 10 from bovine spleen as a ***TNF*** . ***alpha*** . ***convertase***
AU Lunn, Charles A.; Fan, Xuedong; Dalie, Barbara; Miller, Kenneth; Zavodny, Paul J.; Narula, Satwant K.; Lundell, Daniel
CS Department of Immunology, Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA
SO FEBS Lett. (***1997***), 400(3), 333-335
CODEN: FEBLAL; ISSN: 0014-5793
PB Elsevier
DT Journal
LA English
AB The authors have purified a protease with characteristics of ***TNF*** . ***alpha*** . ***convertase*** from bovine spleen membranes. Peptide sequencing of the purified protein identified it as ADAM 10 (Genbank accession no. Z21961). This metalloprotease cleaves a recombinant proTNF.alpha. substrate to mature TNF.alpha., and can cleave a synthetic peptide substrate to yield the mature TNF.alpha. amino terminus in vitro. The enzyme is sensitive to a ***hydroxamate*** inhibitor of MMPs, but insensitive to phosphoramidon. In addn., cloned ADAM 10 mediates proTNF.alpha. processing in a processing-incompetent cell line.

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 7
AN 1997:64517 CAPLUS
DN 126:156259
TI Further evidence for a common mechanism for shedding of cell surface proteins
AU Muellberg, Juergen; Rauch, Charles T.; Wolfson, Martin F.; Castner, Beverly; Fitzner, Jeffrey N.; Otten-Evans, Carol; Mohler, Kendall M.; Cosman, David; Black, Roy A.
CS Immunex Corporation, 51 University Street, Seattle, WA, 98101, USA
SO FEBS Lett. (***1997***), 401(2,3), 235-238
CODEN: FEBLAL; ISSN: 0014-5793
PB Elsevier
DT Journal
LA English
AB Pro-TNF.alpha., Steel factor, type II IL-1R and IL-2R.alpha. were expressed in COS-7 cells and the generation of their sol. forms was examd. The release of all four proteins was strongly stimulated by the phorbol ester PMA and completely blocked by a ***hydroxamate*** -based inhibitor of metalloproteases. COS-7 cell membranes were found to cleave various synthetic pro-TNF.alpha. peptides with the same specificity as a partially purified ***TNF*** . ***alpha*** . ***converting*** ***enzyme*** purified from human monocytic cells, suggesting that the same enzyme may be responsible for at least some of the COS-7 cell shedding activity.

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2001 ACS
AN 2000:833554 CAPLUS
DN 134:4950
TI Preparation of 1-phenylsulfonylazine-2-***hydroxamates*** as metalloproteinase inhibitors
IN Zook, Scott E.; Dagnino, Raymond, Jr.; Deason, Michael E.; Bender, Steven L.; Melnick, Michael J.
PA Agouron Pharmaceuticals, Inc., USA
SO U.S., 45 pp., Cont.-in-part of U.S. 5,753,653.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6153757	A	20001128	US 1998-11971	19980629
WO 9720824	A1	19970612	WO 1996-US19328	19961205 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5753653	A	19980519	US 1996-759713	19961206 <--
PRAI US 1995-41496	P	19951208		
WO 1996-US19328	W	19961205		
US 1996-759713	A2	19961206		
US 1995-569766	A2	19951208		

OS MARPAT 134:4950
AB RZZ1SO2NR1CHR2CONHOH [I; R = (hetero)aryl; R1R2 = atoms to complete a heterocyclic ring; Z = O or S; Z1 = 1,4-phenylene] were prepd. Thus, (R)-N-hydroxy-1-[4-(4-chlorophenoxy)benzenesulfonyl]-4-(tert-butoxycarbonyl)piperazine-2-carboxamide (m.p. 94.6.degree.), prepd. from (R)-piperazine-2-carboxylic acid in 4 steps, demonstrated 77.6% inhibition of lung metastases in a female mouse Lewis lung carcinoma model at 50 mg/kg (i.p.).
RE.CNT 124
RE
(1) Abdel-Meguid; Biochemistry 1994, V33(39), P11671 CAPLUS

(2) Aebischer; Helvetica Chimica Acta 1989, V72, P1043 CAPLUS
(3) Amatore; Journal of Organometallic Chemistry 1990, V390(3), P389 CAPLUS
(4) Anon; EP 276436 1988 CAPLUS
(5) Anon; EP 438223 1991 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2001 ACS
AN 1998:608610 CAPLUS
DN 129:216923
TI Preparation of peptidyl reverse ***hydroxamate*** derivatives as metalloprotease inhibitors
IN Andrews, Robert Carl; Andersen, Marc Werner; Stanford, Jennifer Badiang; Bubacz, Dulcie Garrido; Chan, Joseph Howing; Cowan, David John; Gaul, Michael David; McDougald, Darryl Lynn; Musso, David Lee; Rabinowitz, Michael Howard; Wiethe, Robert William
PA Glaxo Group Ltd., UK
SO PCT Int. Appl., 164 pp. CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9838179	A1	19980903	WO 1998-EP1015	19980224 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9868223	A1	19980918	AU 1998-68223	19980224 <--
BR 9807763	A	20000222	BR 1998-7763	19980224
EP 1019386	A1	20000719	EP 1998-913575	19980224

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

NO 9904103	A	19991025	NO 1999-4103	19990825
PRAI US 1997-39112	P	19970226		
WO 1998-EP1015	W	19980224		

OS MARPAT 129:216923
AB A family of matrix metalloproteinase (MMP) inhibitors having general structural formula I [W = reverse hydroxamic acid group N(OH)CHO; R1 .noteq. H; R4 = lipophilic substituent; R5 = H, alkyl; R6 = heteroaryl; preferably, R1 = Me, Et, CHMe2, Pr, CH2CH2CF3; R2 = CH2CHMe2, CHMeEt; R3 = H; R4 = CMe3, CHMeEt, CHMeOMe, 2-(2-pyridylcarbonylamino)ethyl; R5 = H; R6 = 2-thiazolyl, 2-pyridyl] is described. Such compds. show potent inhibition of MMP's, cell-free tumor necrosis factor (TNF) convertase enzyme and TNF release from cells, and in some cases inhibit TNF convertase and TNF release from cells in preference to matrix metalloproteases. Thus, reverse ***hydroxamate*** peptide II, prepd. in 11 steps from Me (3R)-hydroxypentanoate, methallyl bromide, O-(tetrahydropyranyl)hydroxylamine, Boc-Lys(Cbz)-OH, and 2-aminothiazole, inhibited ***TNF*** . ***alpha*** . ***converting*** ***enzyme*** , collagenase-1, collagenase-3, gelatinase B, and stromelysin 1 all with Ki <100 nm. II also inhibited TNF.alpha. release with IC50 <100 nM.

L6 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2001 ACS
AN 1997:655428 CAPLUS
DN 127:304777
TI Mammalian ***tumor*** ***necrosis*** ***factor*** ***alpha*** ***convertase*** , recombinant expression and purification, and screening for hydroxamic acid deriv. or other inhibitors useful for disease treatment
IN McGeehan, Gerard M.; Becherer, James David; Moss, Marcia L.; Schoenen, Frank J.; Rocque, Warren J.; Chen, Wen-Ji; Didsbury, John R.; Jin, Shiow-Lian Catherine
PA Glaxo Group Limited, UK; McGeehan, Gerard M.; Becherer, James David; Moss, Marcia L.; Schoenen, Frank J.; Rocque, Warren J.; Chen, Wen-Ji; Didsbury, John R.; Jin, Shiow-Lian Catherine
SO PCT Int. Appl., 132 pp. CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9735538	A2	19971002	WO 1997-EP1497	19970325 <--
WO 9735538	A3	19971120		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,

GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
CA 2249985 AA 19971002 CA 1997-2249985 19970325 <--
AU 9722913 A1 19971017 AU 1997-22913 19970325 <--
EP 900272 A2 19990310 EP 1997-915426 19970325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2000507943 T2 20000627 JP 1997-534033 19970325
PRAI US 1996-620663 A 19960326
WO 1997-EP1497 W 19970325
AB The present invention relates to tumor necrosis factor .alpha. (TNF.alpha.), and more specifically to the enzyme ***TNF*** . ***alpha*** .-***convertase*** (TNF.alpha.-con) that can proteolytically convert TNF.alpha. precursor to mature TNF.alpha.. The present invention provides DNA sequences encoding mammalian TNF.alpha.-con and functional equiv. thereof, recombinant expression vectors comprising said DNA sequences, host cell lines comprising said expression vectors, inhibitors of TNF.alpha.-con, inhibitors modified for use as ligands for affinity purifn. of TNF.alpha.-con, and methods for treating diseases or conditions resulting from abnormal levels of TNF.alpha. in a mammalian subject. The general invention is exemplified by prepn. of a biotinylated inhibitor of TNF.alpha.-con.

L6 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2001 ACS
AN 1997:489857 CAPLUS
TI The inhibition of metalloproteinases by macrocyclic sulfonamide ***hydroxamates*** .
AU Cherney, Robert J.; Meyer, Dayton T.; Wang, Li; Xue, Chu-Baio; Copeland, Robert A.; Arner, Elizabeth C.; Jaffee, Bruce D.; Covington, Maryanne B.; Decicco, Carl P.
CS Experimental Station, DuPont Merck Pharmaceutical Co., Wilmington, DE, 19880-0500, USA
SO Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, September 7-11 (***1997***), MEDI-099 Publisher: American Chemical Society, Washington, D. C. CODEN: 64RNAO
DT Conference; Meeting Abstract
LA English
AB Metalloproteinases are involved in the breakdown of connective tissues and cartilage as assocd. with rheumatoid and osteoarthritis. As a result, we became interested in the inhibition of several zinc-dependent endopeptidases including matrix metalloproteinases (MMPs) and the TNF-converting enzyme, ***TACE*** . In order to gain metabolic stability and increase potency for our inhibitors, we synthesized a series of macrocyclic ***hydroxamates*** . The macrocycles are linked from P1 to P2' through a sulfonamide and are represented by the general formula 1.

L6 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2001 ACS
AN 1997:489854 CAPLUS
TI Novel cyclophane inhibitors of matrix metalloproteinases and ***TNF*** -. ***alpha*** . ***converting*** ***enzyme*** .
AU Decicco, Carl P.; Nelson, David J.; Xue, C. -B.; Hardman, Karl; Copeland, Robert; Covington, Maryanne; Magolda, Ron; Arner, Elizabeth
CS Chemical and Physical Science and Inflammatory Diseases Research, Dupont Merck Pharmaceutical Company, Wilmington, DE, 19880-0500, USA
SO Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, September 7-11 (***1997***), MEDI-096 Publisher: American Chemical Society, Washington, D. C. CODEN: 64RNAO
DT Conference; Meeting Abstract
LA English
AB A novel series of 14,15 and 16-membered ring cyclophane ***hydroxamates*** was designed based on the extended conformation of the corresponding peptide based succinate hydroxamic acid inhibitors of metalloproteinases. The key step in the synthesis features a high yielding cyclization of a p-hydroxy Ph group in P2' to a 3-carbon bromide installed in P1. The resulting compds. were detd. to be potent inhibitors of MMPs and ***TACE*** . The prototype 14 membered ring cyclophane was crystd. in the active site of MMP-3 confirming the extended binding conformation of the inhibitor. The synthesis, in vitro and in vivo profile of these inhibitors will be presented.

L6 ANSWER 13 OF 15 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1997:428711 BIOSIS
DN PREV199799727914
TI The inhibition of metalloproteinases by macrocyclic sulfonamide ***hydroxamates*** .
AU Cherney, Robert J.; Meyer, Dayton T.; Wang, Li; Xue, Chu-Baio; Copeland, Robert A.; Arner, Elizabeth C.; Jaffee, Bruce D.; Covington, Maryanne B.; Decicco, Carl P.
CS The DuPont Merck Pharmaceutical Co., Chemical and Physical Sci. and Inflammatory Diseases Res., Experimental Stn., Wilmington, DE 19880-0500 USA

SO Abstracts of Papers American Chemical Society, (1997) Vol. 214, No. 1-2, pp. MEDI 99.
Meeting Info.: 214th American Chemical Society National Meeting Las Vegas, Nevada, USA September 7-11, 1997
ISSN: 0065-7727.
DT Conference; Abstract
LA English

L6 ANSWER 14 OF 15 DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1997-43876 DRUGU C B P
TI Novel cyclophane inhibitors of matrix metalloptoteinases and ***TNF***
- ***alpha*** ***converting*** ***enzyme*** .
AU Decicco C P; Nelson D J; Xue C B; Hardman K; Copeland R; Covington M; Arner E
CS DuPont-Merck
LO Wilmington, Del., USA
SO Abstr.Pap.Am.Chem.Soc. (214 Meet., Pt. 1, MEDI 096, 1997)
CODEN: ACSRAL
ISSN: 0065-7727
AV Chemical and Physical Science and Inflammatory Diseases Research, The
DuPont Merck Pharmaceutical Company, Wilmington, DE, 19880-0500. U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature
AB A novel series of 14, 15 and 16-membered ring cyclophane
hydroxamates was designed based on the extended confirmation of
the corresponding peptide-based succinate hydroxamic acid inhibitors of
metalloproteinases. The key step in the synthesis involved a high
yielding cyclization of a p-hydroxy phenyl group in P2' to a 3-carbon
bromide installed in P1. The resulting compounds were potent inhibitors
of MMPs and ***TACE*** . The prototype 14-membered ring cyclophane
was crystallized in the active site of MMP-3 confirming the extended
binding conformation of the inhibitor. The synthesis, in-vitro and
in-vivo profile of these inhibitors, such as SE-205, were presented.
(conference abstract).

L6 ANSWER 15 OF 15 IFIPAT COPYRIGHT 2001 IFI
AN 2840886
IFIPAT;IFIUDB;IFICDB
TI INHIBITORS OF TNF-ALPHA SECRETION; AMINO ACID DERIVATIVES
INF Black, Roy A, Seattle, WA
Fitzner, Jeffrey N, Seattle, WA
Sleath, Paul R, Seattle, WA
IN Black Roy A; Fitzner Jeffrey N; Sleath Paul R
PAF Immunex Corporation, Seattle, WA
PA Immunex Corp (9809)
EXNAM Conrad, Joseph
AG Malaska, Stephen L
PI US 5629285 19970513 (CITED IN 003 LATER PATENTS)
AI US 1996-651363 19960522
XPD 23 Aug 2013
RLI US 1993-110601 19930823 CONTINUATION-IN-PART ABANDONED
US 1994-292547 19940818 DIVISION
FI US 5629285 19970513
DT UTILITY
FS CHEMICAL
CLMN 19
AB Compounds and methods are disclosed that are useful in inhibiting the
TNF - ***Alpha*** ***converting*** ***enzyme*** (
TACE) responsible for cleavage of TNF- Alpha precursor to
provide biologically active TNF- Alpha . The compounds employed in the
invention are peptidyl derivatives having active groups capable of
inhibiting ***TACE*** such as, ***hydroxamates*** , thiols,
phosphoryls and carboxyls.

=> file uspatfull
COST IN U.S. DOLLARS
SINCE FILE TOTAL

ENTRY SESSION
FULL ESTIMATED COST
134.65 170.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE TOTAL

ENTRY SESSION
CA SUBSCRIBER PRICE
-7.06 -7.06

FILE 'USPATFULL' ENTERED AT 16:26:19 ON 19 JUN 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 19 Jun 2001 (20010619/PD)
FILE LAST UPDATED: 19 Jun 2001 (20010619/ED)
HIGHEST PATENT NUMBER: US6249914
CA INDEXING IS CURRENT THROUGH 19 Jun 2001 (20010619/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 19 Jun 2001 (20010619/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2001
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2001

>>> Page images are available for patents from 1/1/1998. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<

```
>>> available for the WIPO
International Patent
Classification      <<<
>>> (IPC) Manuals, editions
1-6, in the /IC1, /IC2,
/IC3, /IC4,     <<<
>>> /IC5, and /IC (/IC6)
fields, respectively.  The
thesauri in     <<<
>>> the /IC5 and /IC fields
include the corresponding
catchword     <<<
>>> terms from the IPC
subject headings and
subheadings.            <<<

This file contains CAS
Registry Numbers for easy
and accurate
substance identification.

=> s l4
            1 "ADAM17"/BI
         6336
"PROTEINASE"/BI
         1356
"PROTEINASES"/BI
         6935
"PROTEINASE"/BI

(("PROTEINASE" OR
"PROTEINASES")/BI)
            0 "ADAM17
PROTEINASE"/BI

(("ADAM17"(W)"PROTEINASE")/B
I)
          644
"METALLOPROTEINASE"/BI
          586
"METALLOPROTEINASES"/BI
          831
"METALLOPROTEINASE"/BI

(("METALLOPROTEINASE" OR
"METALLOPROTEINASES")/BI)
            1 "ADAM17"/BI
            0
"METALLOPROTEINASE
ADAM17"/BI

(("METALLOPROTEINASE"(W)"ADA
M17")/BI)
        33958 "PRO"/BI
          428 "PROS"/BI
        34268 "PRO"/BI
                (("PRO" OR
"PROS")/BI)
        30736 "TUMOR"/BI
        21039 "TUMORS"/BI
        36424 "TUMOR"/BI
                (("TUMOR"
OR "TUMORS")/BI)
        12581 "NECROSIS"/BI
            1
"NECROSISES"/BI
        12582 "NECROSIS"/BI

(("NECROSIS" OR
"NECROSISES")/BI)
       321994 "FACTOR"/BI
       293260 "FACTORS"/BI
       503455 "FACTOR"/BI
                (("FACTOR"
OR "FACTORS")/BI)
        40750 "CLEAVAGE"/BI
         1192
"CLEAVAGES"/BI
        40982 "CLEAVAGE"/BI

(("CLEAVAGE" OR
"CLEAVAGES")/BI)
        74834 "ENZYME"/BI
        61736 "ENZYMES"/BI
        91672 "ENZYME"/BI
                (("ENZYME"
OR "ENZYMES")/BI)
            0 "PRO TUMOR
NECROSIS FACTOR CLEAVAGE
ENZYME"/BI

(("PRO"(W)"TUMOR"(W)"NECROSI
S"(W)"FACTOR"(W)"CLEAVAGE"(W
)"ENZY
                ME")/BI)
        33958 "PRO"/BI
          428 "PROS"/BI
        34268 "PRO"/BI
                (("PRO" OR
"PROS")/BI)
        30736 "TUMOR"/BI
        21039 "TUMORS"/BI
        36424 "TUMOR"/BI
                (("TUMOR"
OR "TUMORS")/BI)
        12581 "NECROSIS"/BI
            1
"NECROSISES"/BI
        12582 "NECROSIS"/BI

(("NECROSIS" OR
"NECROSISES")/BI)
       321994 "FACTOR"/BI
       293260 "FACTORS"/BI
       503455 "FACTOR"/BI
                (("FACTOR"
OR "FACTORS")/BI)
       320774 "ALPHA"/BI
          256 "ALPHAS"/BI
       320794 "ALPHA"/BI
                (("ALPHA"
OR "ALPHAS")/BI)
       627666
"PROCESSING"/BI
         9597
"PROCESSINGS"/BI
       628354
"PROCESSING"/BI

(("PROCESSING" OR
"PROCESSINGS")/BI)
        74834 "ENZYME"/BI
        61736 "ENZYMES"/BI
        91672 "ENZYME"/BI
                (("ENZYME"
OR "ENZYMES")/BI)
            0 "PRO-TUMOR
NECROSIS FACTOR-.ALPHA.-
PROCESSING ENZYME"/BI

(("PRO"(W)"TUMOR"(W)"NECROSI
S"(W)"FACTOR"(W)"ALPHA"(W)"P
ROCESS

ING"(W)"ENZYME")/BI)
           60 "TACE"/BI
            2 "TACES"/BI
           62 "TACE"/BI,
                (("TACE" OR
"TACES")/BI)
         6336
"PROTEINASE"/BI
         1356
"PROTEINASES"/BI
         6935
"PROTEINASE"/BI

(("PROTEINASE" OR
"PROTEINASES")/BI)
            0 "TACE
PROTEINASE"/BI

(("TACE"(W)"PROTEINASE")/BI)
           60 TACE/BI
            2 TACES/BI
           62 TACE/BI
                (("TACE OR
TACES)/BI)
         5574 "TNF"/BI
           99 "TNFS"/BI
         5588 "TNF"/BI
                (("TNF" OR
"TNFS")/BI)
       320774 "ALPHA"/BI
          256 "ALPHAS"/BI
       320794 "ALPHA"/BI
                (("ALPHA"
OR "ALPHAS")/BI)
          266
"CONVERTASE"/BI
          124
"CONVERTASES"/BI
          301
"CONVERTASE"/BI

(("CONVERTASE" OR
"CONVERTASES")/BI)
           20 "TNF-.ALPHA.
CONVERTASE"/BI

(("TNF"(W)"ALPHA"(W)"CONVERT
ASE")/BI)
         5574 "TNF"/BI
           99 "TNFS"/BI
         5588 "TNF"/BI
                (("TNF" OR
"TNFS")/BI)
       320774 "ALPHA"/BI
          256 "ALPHAS"/BI
       320794 "ALPHA"/BI
                (("ALPHA"
OR "ALPHAS")/BI)
       225587
"CONVERTING"/BI
            6
"CONVERTINGS"/BI
       225587
"CONVERTING"/BI

(("CONVERTING" OR
"CONVERTINGS")/BI)
        74834 "ENZYME"/BI
```

```
        61736 "ENZYMES"/BI
        91672 "ENZYME"/BI
                (("ENZYME"
OR "ENZYMES")/BI)
           36 "TNF-.ALPHA.
CONVERTING ENZYME"/BI

(("TNF"(W)"ALPHA"(W)"CONVERT
ING"(W)"ENZYME")/BI)
         5574 "TNF"/BI
           99 "TNFS"/BI
         5588 "TNF"/BI
                (("TNF" OR
"TNFS")/BI)
       320774 "ALPHA"/BI
          256 "ALPHAS"/BI
       320794 "ALPHA"/BI
                (("ALPHA"
OR "ALPHAS")/BI)
       627666
"PROCESSING"/BI
         9597
"PROCESSINGS"/BI
       628354
"PROCESSING"/BI

(("PROCESSING" OR
"PROCESSINGS")/BI)
        18013 "PROTEASE"/BI
        11194
"PROTEASES"/BI
        22142 "PROTEASE"/BI

(("PROTEASE" OR
"PROTEASES")/BI)
           0 "TNF-.ALPHA.
PROCESSING PROTEASE"/BI

(("TNF"(W)"ALPHA"(W)"PROCESS
ING"(W)"PROTEASE")/BI)
        30736 "TUMOR"/BI
        21039 "TUMORS"/BI
        36424 "TUMOR"/BI
                (("TUMOR"
OR "TUMORS")/BI)
        12581 "NECROSIS"/BI
            1
"NECROSISES"/BI
        12582 "NECROSIS"/BI

(("NECROSIS" OR
"NECROSISES")/BI)
       321994 "FACTOR"/BI
       293260 "FACTORS"/BI
       503455 "FACTOR"/BI
                (("FACTOR"
OR "FACTORS")/BI)
       320774 "ALPHA"/BI
          256 "ALPHAS"/BI
       320794 "ALPHA"/BI
                (("ALPHA"
OR "ALPHAS")/BI)
          266
"CONVERTASE"/BI
          124
"CONVERTASES"/BI
          301
"CONVERTASE"/BI

(("CONVERTASE" OR
"CONVERTASES")/BI)
            3 "TUMOR
NECROSIS FACTOR .ALPHA.
CONVERTASE"/BI

(("TUMOR"(W)"NECROSIS"(W)"FA
CTOR"(W)"ALPHA"(W)"CONVERTAS
E")/BI
                )
        30736 "TUMOR"/BI
        21039 "TUMORS"/BI
        36424 "TUMOR"/BI
                (("TUMOR"
OR "TUMORS")/BI)
        12581 "NECROSIS"/BI
            1
"NECROSISES"/BI
        12582 "NECROSIS"/BI

(("NECROSIS" OR
"NECROSISES")/BI)
       321994 "FACTOR"/BI
       293260 "FACTORS"/BI
       503455 "FACTOR"/BI
                (("FACTOR"
OR "FACTORS")/BI)
       320774 "ALPHA"/BI
          256 "ALPHAS"/BI
       320794 "ALPHA"/BI
                (("ALPHA"
OR "ALPHAS")/BI)
       225587
"CONVERTING"/BI
            6
"CONVERTINGS"/BI
       225587
"CONVERTING"/BI

(("CONVERTING" OR
"CONVERTINGS")/BI)
        74834 "ENZYME"/BI
        61736 "ENZYMES"/BI
        91672 "ENZYME"/BI
                (("ENZYME"
OR "ENZYMES")/BI)
           17 "TUMOR
NECROSIS FACTOR-.ALPHA.
CONVERTING ENZYME"/BI

(("TUMOR"(W)"NECROSIS"(W)"FA
CTOR"(W)"ALPHA"(W)"CONVERTIN
G"(W)"

ENZYME")/BI)
          632 HYDROXAMATE
          291 HYDROXAMATES
          784 HYDROXAMATE

(HYDROXAMATE OR
HYDROXAMATES)
      2425056 PY<1999
L7          6 L3 AND
PY<1999

=> d ti 1-6

L7   ANSWER 1 OF 6
USPATFULL
TI     Metalloproteinase
inhibitors and intermediates
useful for their
       preparation

L7   ANSWER 2 OF 6
USPATFULL
TI     Thioaryl sulfonamide
hydroxamic acid compounds

L7   ANSWER 3 OF 6
USPATFULL
TI     Mammalian   ***TNF***
-.  ***alpha***  .
***convertases***

L7   ANSWER 4 OF 6
USPATFULL
TI     Metalloproteinase
inhibitors, pharmaceutical
compositions containing
       them and their
pharmaceutical uses

L7   ANSWER 5 OF 6
USPATFULL
TI     Inhibitors of TNF-
.alpha. secretion

L7   ANSWER 6 OF 6
USPATFULL
TI     Inhibitors of TNF-
.alpha. secretion


=> d pn 1-6

L7   ANSWER 1 OF 6
USPATFULL
PI     US 6153757  20001128
       WO 9720824  19970612
<--

L7   ANSWER 2 OF 6
USPATFULL
PI     US 6087359  20000711
       WO 9839313  19980911
<--

L7   ANSWER 3 OF 6
USPATFULL
PI     US 5853977  19981229
<--

L7   ANSWER 4 OF 6
USPATFULL
PI     US 5753653  19980519
<--

L7   ANSWER 5 OF 6
USPATFULL
PI     US 5629285  19970513
<--

L7   ANSWER 6 OF 6
USPATFULL
PI     US 5594106  19970114
<--


=> log y
COST IN U.S. DOLLARS
SINCE FILE      TOTAL

ENTRY    SESSION
```

FULL ESTIMATED COST
6.94 177.63

DISCOUNT AMOUNTS (FOR
QUALIFYING ACCOUNTS)
SINCE FILE TOTAL

ENTRY SESSION
CA SUBSCRIBER PRICE
0.00 -7.06

STN INTERNATIONAL LOGOFF AT
16:27:34 ON 19 JUN 2001